Projects

Single Technology Appraisals (STAs), Highly Specialised Technology Appraisals (HSTs) and Cost Comparisons (CCs)

Project Title	Report Status
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31)	Report due: April 2026 Status: Ongoing
STA Lenacapavir for preventing HIV-1 in people 16 years and over	Report submitted: December 2025 Status: Ongoing
Zuranalone for treating postnatal depression	Report submitted: May 2025 Status: Ongoing
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over	Report submitted: February 2025 Status: Ongoing
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy	Report submitted: January 2025 Status: Ongoing
Insulin icodec for treating type 2 diabetes	Report submitted: December 2024 Status: Appraisal suspended until further notice
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer	Report submitted: July 2024 Guidance published: 08/05/2025
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over	Report submitted: May 2024 Guidance published: 22/05/2024
Risankizumab for treating moderately to severely active ulcerative colitis	Report submitted: January 2024 Guidance published: 22/08/2024
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome	Report submitted: March 2023 Guidance published: 22/05/2024
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable	Report submitted: July 2022 Guidance published: 25/10/2023
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy	Report submitted: June 2022 Guidance published: 10/05/2023